Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy Authors: Mengqi Yang, Yedong Huang, Weiye Qian, Junye Zhu, Liu Fei, Zhixin Jiao, Jian Wang, Yifan Wang, Wenbo Zhu, Shun Chen, Peipei Gong, Ziheng Wang, Zhichao Lu, Rujun Liu, Zhining Liu, Qiaojun Hong, Qingyu Luo, Lin Zhang Published: 2026 ABSTRACT AbstractTherapeutic outcomes in solid tumors are shaped by drug potency and by heterogeneous tumor microenvironments that restrict vascular access, stromal penetration, local release, immune activation and durable response. Multifunctional nanotherapeutics have been developed to engage these barriers through pharmacokinetic optimization, vascular and stromal modulation, endogenous and exogenous stimuli-responsive release, immune-oriented intervention and imaging-guided treatment. However, the field remains challenged by heterogeneous human enhanced permeability and retention effects, uncertain translation of active targeting, context-dependent stromal biology, incomplete immune readouts and increasing chemistry-manufacturing-controls complexity as additional modules are integrated. This review organizes nanoplatforms through a tumor microenvironment phenotype-informed design logic that links biological barriers to design objectives, module choices, measurable readouts, evidence strength and translational constraints. Within this framework, we critically examine representative nanotherapeutic strategies across pharmacokinetic and biodistribution-oriented design, vascular and stromal normalization, tumor microenvironment-responsive activation, immune priming and intratumoral reprogramming, and clinically relevant theranostic approaches. We further discuss route of administration, patient stratification, safety, value assessment and rational platform simplification, emphasizing that future progress is more likely to depend on phenotype-matched and evidence-stratified deployment than on indiscriminate functional stacking. Introduction Solid tumor progression and therapeutic response are shaped by a complex tumor microenvironment that operates as a spatially organized and dynamically evolving tissue ecosystem. This microenvironment comprises abnormal blood and lymphatic vessels, extracellular matrix networks, cancer-associated fibroblasts, immune cells, metabolic gradients and soluble mediators, with substantial variation across tumor types, between patients and among regions within the same lesion. Such heterogeneity influences how therapeutics enter tumor tissue, move through the interstitium, remain locally available, engage immune and stromal components and generate durable responses. For nanotherapeutics, the TME therefore represents both a biological barrier to delivery and a source of phenotype-specific design cues that can inform carrier architecture, release behavior, targeting strategy and combination scheduling. Within this heterogeneous biological context, systemic pharmacotherapy remains the backbone of management for most solid tumors. Combination regimens based on platinum compounds, taxanes and fluoropyrimidines are still standard in many disease settings and lines of therapy [1, 2]. Small-molecule inhibitors and monoclonal antibodies have further expanded systemic options by selectively targeting key oncogenic pathways, including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR), B-Raf proto-oncogene (BRAF) and anaplastic lymphoma kinase (ALK) [3]. Immune checkpoint inhibitors directed against programmed cell death protein-1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) add an immunomodulatory layer to these approaches. Together, these modalities have improved survival or allowed more durable disease control in several tumor types and have been incorporated into national and international guidelines [2, 4]. These advances, however, coexist with constraints that are increasingly difficult to ignore. Cytotoxic chemotherapy and several targeted agents induce dose-dependent systemic toxicities, such as myelosuppression, hepatic and renal injury, and gastrointestinal adverse events, which limit the dose intensity and duration that patients can tolerate [5, 6]. At the same time, most small-molecule and biologic drugs distribute widely in the circulation, while only a limited and often heterogeneous fraction reaches the tumor, resulting in insufficient and uneven local exposure [7]. Across chemotherapy, targeted therapy and immunotherapy, primary and acquired resistance and subsequent relapse remain common. In this context, simply switching agents or adjusting schedules offers progressively smaller gains, because the surrounding tumor milieu becomes a major factor that shapes treatment outcomes [3, 4, 7–9]. More specifically, several recurring TME features are particularly relevant to nanotherapeutic design: abnormal vasculature, dense stroma and an immunosuppressive immune landscape [10–14]. Disorganized neovessels and uneven perfusion generate regions of chronic hypoxia and acidosis [12, 15]. Enhanced deposition of extracellular matrix and activation of cancer-associated fibroblasts build tangible physical barriers to molecular transport [13]. Regulatory T cells, myeloid-derived suppressor cells and tumor-associated macrophages skewed toward an M2-like phenotype accumulate, while immunosuppressive mediators are upregulated, keeping local immune reactivity at a low level [14, 16]. Under such conditions, even structurally optimized drugs or more potent inhibition of single signaling pathways can have their effects diluted, misdirected or compartmentalized by the architecture and dynamics of the TME [11, 17]. Nanomedicine-based delivery systems have been developed in part as a response to this layered constraint [18, 19]. Early nanoformulations, such as liposomes and polymeric micelles, were primarily designed to improve solubility and pharmacokinetics and to exploit enhanced vascular permeability and impaired lymphatic drainage for passive tumor accumulation [18, 20, 21]. Their main aims were to reduce systemic toxicity, smooth plasma concentration–time profiles and modestly increase drug exposure within tumor tissue [18, 20, 21]. Disease-focused reviews have systematically summarized how nanoparticle drug delivery systems have been applied to specific tumor entities, such as triple-negative breast cancer, highlighting improvements in pharmacokinetics, tumor accumulation and targeting specificity, while also underscoring persistent challenges related to intratumoral heterogeneity and limited penetration [22]. As understanding of TME biology has deepened, these systems have been progressively re-envisioned as functional platforms rather than simple carriers [13, 19]. In a single construct, modules for vascular modulation, stromal remodeling and immune regulation can be combined; surface ligands can be used to engage specific TME cell populations; and stimuli-responsive components can modulate drug release in situ [13, 19, 23]. In some designs, imaging probes and photothermal, photodynamic, sonodynamic or radiosensitizing elements are also incorporated, opening the possibility of integrated diagnostic and therapeutic use [19, 24, 25]. This shift has moved nanotherapeutic design from general exposure modification toward more explicit attempts to match carrier functions with phenotype-specific TME barriers. The present review adopts a TME phenotype-informed design logic to examine how recurrent structural and functional features of solid tumors shape drug delivery, therapeutic response and translational feasibility. It discusses how multifunctional nanoplatforms engage these features through pharmacokinetic and biodistribution-oriented design, vascular and stromal modulation, TME-responsive activation, immune-oriented intervention and imaging-guided therapy. We further examine how unresolved issues in manufacturing scale-up, prediction of in vivo behavior, safety assessment, biological heterogeneity and clinical value define the space between experimental constructs and clinical application [18, 20, 21, 24]. We also briefly consider how data-driven design and real-world evaluation may support the development and deployment of TME-oriented nanotherapies [26–28]. Design logic of multifunctional nanotherapies targeting the tumor microenvironment Key tumor microenvironmental barriers and corresponding design objectives The tumor microenvironment features that shape drug delivery and therapeutic response in solid tumors can be grouped into three levels that are particularly relevant for nanomedicine design, namely the vasculature and interstitium, the extracellular matrix, and the immune compartment [29–31]. At the vascular and interstitial level, pathological angiogenesis and altered fluid dynamics restrict the entry of blood-borne carriers into the tumor and make their distribution within the tissue highly uneven [31–33]. At the matrix level, abundant deposition of extracellular matrix (ECM) components and sustained activation of cancer-associated fibroblasts (CAFs) densify the stroma and create major physical barriers to the diffusion of nanoparticles and macromolecules [30, 32, 34]. On the immune side, suppressive cell populations predominate and immunosuppressive mediators are upregulated, which weakens antitumor immune responses and compromises the durability of immunotherapy [29, 35]. Within this landscape, TME-oriented nanoplatforms tend to converge on a set of relatively well-defined design objectives [31, 36]. At the vascular and interstitial scale, insufficient perfusion and dense stromal architecture limit the ability of nanocarriers to enter tumor tissue and access deeper regions, making enhancement of functional perfusion and penetration a primary design concern [31, 33, 36]. Beyond initial delivery, pharmacokinetic considerations become increasingly relevant, as prolonged intratumoral retention and moderated release kinetics can extend local drug exposure and increase the effective time–concentration integral within the lesion [33, 37]. At a further level of complexity, many nanoplatforms are also engineered to interact with defined immune cell populations or signaling pathways, with the aim of partially relieving immunosuppressive features of the tumor microenvironment and creating conditions more permissive for systemic immunotherapy or rational combination regimens [9, 29, 35]. Subsequent choices of interface parameters and functional module combinations are, in essence, concrete routes through which these overarching aims are pursued, and they form the basis for the design logic outlined in the following subsections [9, 31, 33, 37]. Nano-bio interface parameters and in vivo behavior Translating these objectives into concrete nanocarrier architectures first requires specifying a set of nano-bio interface parameters that govern in vivo behavior [33, 37]. Particle size, surface charge, hydrophilicity, shape and mechanical properties together define the basic constraints on how a platform circulates, extravasates and moves within tissues [33, 37–39]. Preclinical studies in animal models consistently indicate that, within the tens to hundreds of nanometers range, there is a trade-off between circulation time, transvascular extravasation and tissue penetration [38–40]. Particle size exerts a strong influence on transport behaviour across both vascular and interstitial barriers. Smaller carriers can more readily pass through endothelial gaps and extracellular matrix pores, yet their rapid renal elimination limits systemic persistence and effective tumor exposure [38, 40]. Larger particles, by contrast, benefit from prolonged circulation and enhanced accumulation at the tumor periphery, but their restricted penetration into deeper tissue regions remains a persistent limitation [33, 38, 40]. For a given tumor type and vascular pore structure, particle size is therefore best treated as a matching variable adjusted to the anatomical and hemodynamic context of each indication [38–40]. Surface charge and hydrophilicity primarily influence plasma protein adsorption, clearance by the mononuclear phagocyte system and overall circulation time [33, 37, 39]. Neutral or mildly negative surfaces are generally associated with longer circulation and lower nonspecific uptake and are therefore suited to designs that prioritize increased lesion exposure [33, 37, 39]. More strongly positive charges can enhance interactions with cell membranes and promote endocytosis, but they require more cautious choices of materials and dosing in light of potential toxicity and immune recognition [33, 39]. The protein corona that forms in biological fluids is widely regarded as a key determinant of the effective surface of a nanoparticle [41–44]. Differences in core materials and surface chemistry lead to distinct corona compositions, which in turn exert integrated effects on endothelial interactions, immune recognition and clearance pathways [41–45]. In practice, these interdependent parameters are tuned in combination to achieve the desired in vivo behavior and provide the physical and pharmacokinetic scaffold on which more specialized functional units can be built. Stimuli-responsive and targeting modules as functional units Building on this scaffold, endogenous and exogenous stimuli-responsive elements together with active targeting modules provide ways to focus nanocarrier action on specific TME regions or cell populations [46–48]. Endogenous stimuli strategies make use of biochemical differences within the TME, including extracellular and intracellular pH gradients, altered redox status, overexpression of proteases and hypoxic conditions [46, 47, 49]. By incorporating bonds or structural motifs that respond to these cues, nanocarriers can undergo structural rearrangement, disassembly or shifts in hydrophilicity within tumor tissue or inside cells, which enables release or activation after local accumulation within tumor tissue or cells [46–48]. Exogenous stimuli modules rely on controllable physical inputs such as near-infrared light, ultrasound, magnetic fields or temperature changes [48, 50, 51]. These inputs are used to enhance local release within a defined time window and, in some designs, to introduce additional photothermal, photodynamic or sonodynamic effects that act in concert with the delivered drug [50, 52]. Targeting modules introduce cellular or tissue selectivity through ligand–receptor recognition or the use of cell-penetrating peptides [53, 54]. Passive accumulation and the enhanced permeability and retention effect remain the baseline mechanisms for tumor localization in most nanoplatforms, but they are subject to substantial variability between tumors and even within the same lesion [55, 56]. Active targeting builds on this baseline by directing carriers toward functional nodes, for example receptors on tumor cells or on key TME cell types such as tumor endothelial cells, cancer-associated fibroblasts and defined immune cell subsets [53, 57, 58]. Penetration motifs further strengthen the ability of carriers to traverse the vascular wall and the extracellular matrix and complement particle size and surface properties in efforts to improve tissue penetration [59]. Many multifunctional platforms can be viewed as combinations of several stimuli-responsive units and a set of targeting or penetration units, with therapeutic and co-therapeutic modules embedded among them to form a specific treatment scheme [47, 48]. As more of these units are assembled within a single construct, questions of complexity and feasibility naturally move to the foreground. Balancing multifunctionality and feasibility These questions become particularly evident in designs that attempt to address several TME barriers at once. Conceptually, such designs tend to move toward functional stacking, with multiple responsive, targeting and co-therapeutic elements integrated into one platform [48]. In practice, increased structural complexity inevitably brings a higher burden in terms of manufacturing scale-up, quality control and safety evaluation [60–62]. The more components and synthetic steps a system contains, the more difficult it becomes to maintain batch-to-batch consistency, long-term stability and a controllable, cost-effective process [60–63]. Trade-offs also arise between material stability and stimuli responsiveness, between prolonged circulation and adequate tissue exposure, and between local intensification of effects and systemic safety [60, 62]. For a given tumor type and combination regimen, a more practical path is to identify the most critical TME barriers and prioritize design objectives accordingly [60, 62]. Only a limited set of core steps is equipped with additional functional modules, while particle interfaces, response intensity and targeting strength are tuned as a coherent compromise that can be characterized and tested [60, 62]. Platforms obtained in this manner retain the specificity of TME-oriented design yet remain relatively compatible with existing pathways for manufacturing, quality control and safety assessment in drug development [61–63]. Recent work has translated these principles into several families of multifunctional nanoplatforms with distinct TME-focused intervention strategies, which are outlined below [48]. The overall design logic linking TME barriers, cross-cutting design objectives, nano-bio interface parameters, functional modules and representative strategy categories is summarized in Fig. 1, which provides a conceptual framework that bridges the design considerations discussed in Sect. 2 and the strategy-oriented classification introduced in Sect. 3. Design logic of TME-oriented multifunctional nanoplatforms. In this schematic, nano-bio interface parameters and functional modules are positioned as intermediate design layers that translate cross-cutting design objectives into implementable intervention strategies. These elements function as modular links between TME barriers and the representative classes of multifunctional nanoplatforms discussed in Sect. 3 Multifunctional nanotherapy strategies and representative systems targeting the tumor microenvironment Within the design logic outlined above, multifunctional nanotherapeutics are organized here according to the dominant TME problem they address [31, 33, 64, 65]. The resulting strategy families correspond to major design objectives: improving pharmacokinetics and biodistribution [33, 37, 53, 66, 67], modulating vascular access and perfusion [11, 12, 15, 68, 69], normalizing or reprogramming stromal barriers [13, 17, 30, 32, 34, 70], enabling endogenous TME-responsive release or activation [46–48], reshaping antitumor immunity [29, 35, 71], and integrating imaging with therapeutic intervention [72–74]. Many platforms span more than one category, but this analytical separation clarifies the biological assumption, supporting readouts and translational constraints behind each design. Table 1 links recurrent TME phenotypes to dominant barriers, design objectives, candidate nanotherapeutic strategies and key translational cautions. Table 1Phenotype-to-design matrix for TME-oriented nanotherapeuticsTME phenotypeDominant barrierDesign objectiveCandidate nanotherapeutic design logicKey translational cautionDesmoplastic/immune-excluded tumorsDense ECM, CAF activation, high interstitial pressure, limited immune-cell entryImprove penetration and reduce physical exclusionStromal normalization, size-transformable carriers, matrix-modulating systems, selective CAF or ECM reprogramming [13, 17, 27, 30, 32, 34, 70]Broad stromal or CAF depletion may worsen tumor biology in some contextsPoorly perfused/hypoxic tumorsUneven blood flow, hypoxia, acidosis, reduced drug distributionImprove perfusion, reduce hypoxia-related resistance, coordinate delivery timingVascular normalization, hypoxia-responsive activation, oxygen-modulating systems, radiosensitizing nanoplatforms [11, 12, 15, 46, 49, 68, 75]Normalization effects are time-dependent and need coordination with PK and release profilesHighly angiogenic/vascular-leaky tumorsAbnormal neovessels, heterogeneous permeability, unstable EPR effectImprove functional vascular access and tumor exposurePK-optimized long-circulating systems, vascular-modulating combinations, imaging-assisted delivery assessment [18, 20, 33, 55, 56, 66, 67]EPR-based accumulation varies across patients, lesions and treatment stagesMacrophage-rich suppressive tumorsM2-like TAMs, suppressive cytokines, poor effector-cell functionRebalance local immune signaling and improve effector-cell activityTAM-targeted nanoparticles, CSF1R/TLR/STING-related modulation, local immunomodulatory delivery [29, 35, 71, 76–80]Immune readouts should distinguish local reprogramming from systemic primingImmune-cold/weakly primed tumorsInsufficient antigen presentation and T-cell primingInitiate or amplify systemic antitumor immunityNanovaccines, lymph-node-targeted antigen/adjuvant delivery, STING or TLR agonist platforms [76, 77, 81–83]Downstream TME changes may reflect systemic primingAcidic/redox-active/enzyme-rich tumorsLocal pH, glutathione, protease activity or ROS gradientsEnable local release or activationpH-, redox-, protease-, ROS- or multi-stimuli-responsive systems [46–49, 84]Endogenous triggers overlap with physiological compartments and vary spatiallyDeep-seated or disseminated tumors requiring monitoringLimited optical access, need for whole-body assessmentLink delivery confirmation with treatment planning or response monitoringMRI-, PET/SPECT- or radionuclide-linked nanotheranostic platforms [72–74, 85–89]Imaging signal should guide selection, dosing or monitoring decisions Phenotype-to-design matrix for TME-oriented nanotherapeutics Pharmacokinetic and biodistribution-oriented design Pharmacokinetic and biodistribution-oriented design represents the entry layer of TME-oriented nanotherapy. Before a platform can exert TME-directed effects, it must achieve sufficient systemic persistence, tumor access and intratumoral retention. Early oncology nanomedicines were largely designed around exposure modification, including prolonged circulation, reduced peak-related toxicity, altered tissue distribution and partial exploitation of the enhanced permeability and retention effect [18, 20, 21, 33]. These objectives remain important, although vascular access and interstitial transport vary substantially across human tumors. Passive targeting through the enhanced permeability and retention effect has long provided a conceptual basis for nanoparticle accumulation in tumors [18, 20, 55]. In preclinical models, leaky tumor vessels and impaired lymphatic drainage can support higher local retention of long-circulating particles. However, human EPR effects vary across tumor types, patients, lesions and treatment stages [55, 56, 66, 67]. Vascular permeability, perfusion, interstitial pressure, stromal density and macrophage uptake also differ within tumors and between metastatic sites. Passive accumulation therefore depends on tumor phenotype and delivery context. Active targeting mainly provides cellular-level selectivity after tumor access has been achieved. Ligand modification can improve binding to tumor cells or TME-associated cells and enhance receptor-mediated internalization in accessible tumor regions [53, 54, 57, 58]. Total tumor accumulation remains constrained by circulation time, endothelial transport, vascular heterogeneity, interstitial pressure, particle size, surface chemistry and protein corona formation [33, 41–45, 53]. Ligand-based designs therefore require biodistribution evidence in addition to cellular uptake data. Vascular normalization and perfusion-oriented design Abnormal tumor vasculature strongly influences nanotherapeutic delivery and response. Tortuous, immature and unevenly perfused vessels create spatial heterogeneity in vascular access, oxygenation, acidity and drug distribution [11, 12, 15, 68]. Increased permeability supports nanoparticle extravasation in selected regions, while poor perfusion, high interstitial pressure and heterogeneous flow limit uniform delivery across the tumor mass [17, 33]. Vascular-oriented design therefore focuses on functional access, perfusion normalization and delivery within a therapeutically useful time window. Vascular normalization seeks to transiently improve vessel structure and function, including pericyte coverage, perfusion, oxygenation and drug distribution [11, 12, 68]. Excessive vascular pruning may reduce blood flow and impair nanoparticle delivery, while insufficient modulation may leave hypoxia and spatially uneven exposure unchanged [12, 68, 75]. The vascular-modulating component, carrier pharmacokinetics and payload release profile need to be coordinated with the normalization window. CRLX101 illustrates this vascular-oriented logic as a cyclodextrin-based camptothecin nanoparticle associated with high intratumoral accumulation, HIF-1α pathway modulation, reduced hypoxic regions and improved drug distribution in selected preclinical or early clinical settings [90–95]. Other vascular-modulating platforms combine low-intensity vascular regulation with cytotoxic therapy, radiotherapy, photodynamic therapy or immunotherapy [17, 68, 69]. Evidence remains uneven, as many studies infer vascular normalization from tumor growth delay or improved combination response, while fewer provide direct readouts of perfusion, vessel maturity, oxygenation, intratumoral drug distribution and the timing of the normalization window. Stromal normalization and reprogramming Stromal barriers represent a second major constraint after vascular access has been established. In many solid tumors, extracellular matrix deposition, cancer-associated fibroblast activation and elevated interstitial fluid pressure restrict the movement of nanoparticles from perivascular regions into deeper tumor tissue [14, 17, 30, 32, 34]. This barrier is particularly prominent in desmoplastic tumors, where collagen, hyaluronan and other matrix components form a dense physical and mechanical network around malignant and immune cells. For nanotherapeutic design, the stromal compartment therefore creates two related objectives: improving tissue penetration and modifying stromal signaling in a way that supports therapeutic response. Early stromal-oriented designs often focused on matrix depletion or enzymatic loosening. Matrix metalloproteinase-responsive nanoparticles and collagenase-loaded systems are representative examples [84, 96]. MMP-responsive particles use peptide sequences cleavable by MMP-2 or MMP-9 to induce size reduction, disassembly or drug release in matrix-rich tumor regions [84], while collagenase or matrix-degrading peptide-loaded platforms aim to lower local collagen or hyaluronan density and reduce interstitial pressure [96]. In preclinical models, these approaches have been associated with ECM loosening, increased penetration distance from vessels, enhanced immune cell infiltration and delayed tumor growth [70, 96, 97]. Stromal remodeling requires careful biological interpretation. The stroma can restrain tumor expansion, shape immune exclusion, regulate vascular compression and influence invasion patterns [13, 17, 70, 97]. Pancreatic cancer studies have shown that broad depletion of stromal elements or carcinoma-associated fibroblasts can accelerate disease progression and worsen immunosuppression in some settings [70, 97]. These findings support a shift from broad stromal removal toward normalization or selective reprogramming in stromal-oriented nanotherapeutic design. CAF heterogeneity further complicates this design problem. Cancer-associated fibroblasts include matrix-producing, inflammatory, myofibroblastic and antigen-presenting-like populations, among others, with functions that can be tumor-promoting, immune-modulating or partly tumor-restraining depending on context [13, 30, 34, 57, 58]. CAF-directed nanoplatforms should define whether they reduce matrix density, alter fibroblast signaling, improve immune access or combine these objectives. Broad CAF suppression and selective modulation of a pro-tumorigenic CAF subset may lead to different biological consequences [98]. Endogenous TME-responsive release and activation Endogenous TME-responsive systems exploit biochemical gradients or pathological cues within tumor tissue to guide therapy-focused release or activation. Acidic pH, elevated intracellular glutathione, overexpressed proteases, reactive oxygen species and hypoxia can trigger drug release, carrier disassembly, charge conversion, size transformation or prodrug activation [46–49, 99]. The design objective is local therapeutic activation based on intrinsic TME signals. Representative designs include pH-responsive carriers, redox-sensitive disulfide systems, protease-responsive carriers activated by enzymes such as MMP-2 or MMP-9, and hypoxia-responsive systems based on oxygen-sensitive linkers, prodrugs or oxygen-modulating components [46, 47, 49, 84, 100]. Trigger specificity remains limited because pH and redox gradients overlap with physiological compartments, protease expression varies across tumor and stromal regions, and hypoxia is spatially unstable. Multi-stimuli-responsive platforms may improve selectivity, with added structural complexity, difficult release characterization and higher analytical burden during translation [48, 60–63]. Immune-oriented nanotherapeutics: systemic priming and intratumoral reprogramming Immune-oriented nanotherapeutics alter the balance between antitumor effector mechanisms and suppressive immune networks. Some systems act through lymph-node targeting and systemic immune priming; others directly modify suppressive immune cells or cytokine networks within the tumor [29, 35, 71]. Nanovaccines represent a major class of systemic immune-priming platforms. Polymeric or lipid nanoparticles can co-deliver tumor antigens and adjuvants that activate pathways such as stimulator of interferon genes or Toll-like receptors [81–83]. By tuning particle size, surface properties and drainage behavior, these formulations can preferentially reach lymph nodes and be taken up by dendritic cells, supporting coordinated antigen presentation and T-cell priming [81–83]. In preclinical models, nanovaccines have been associated with increased antigen-specific CD8⁺ T cells, memory or tissue-resident T-cell populations and improved tumor control, particularly when combined with immune checkpoint inhibitors [81, 83]. Their TME effects often occur downstream of systemic immune activation. Direct intratumoral immune reprogramming follows a different delivery and mechanism sequence. These platforms act within tumor tissue on suppressive cell populations or local immune signaling pathways. Examples include nanoparticles delivering CSF1R inhibitors, TLR agonists, transforming growth factor-beta siRNA or other immunomodulatory agents to tumor-associated macrophages, regulatory T cells or myeloid-derived suppressor cells [78–80]. The aim is to shift macrophage polarization, reduce suppressive immune-cell activity, alter cytokine profiles and increase effector-cell infiltration in the tumor. These approaches depend strongly on tumor accumulation, local release and cellular selectivity within the suppressive TME. A third group combines systemic priming with intratumoral reprogramming. For example, nanovaccines or STING-activating systems may be paired with checkpoint blockade or with platforms that reduce macrophage- or Treg-mediated suppression [76–81, 83]. These combinations are attractive because antitumor immunity often requires both effective T-cell generation and a tumor site that permits effector-cell entry and function. Mechanism attribution can be difficult, as increased intratumoral CD8⁺ T cells, cytokine activation or tumor control may reflect lymph-node priming, local TME modulation, checkpoint synergy or several processes acting together. Imaging-guided and theranostic nanotherapeutics Imaging-guided and theranostic nanotherapeutics integrate diagnostic readouts with therapeutic intervention. Optical and near-infrared platforms remain common in preclinical studies because they support high-contrast visualization, externally controlled activation and coupling with photothermal or photodynamic therapy [101–103]. In acidic, reducing or hypoxic tumor regions, multicomponent nanovesicles or size-transformable nanocapsules can generate imaging contrast while enabling local release, radiosensitization, photothermal therapy or photodynamic effects [101–104]. Their translational use is shaped by tissue penetration, lesion depth, light accessibility and the need for specialized activation devices, making them more suitable for superficial, endoscopically accessible or intraoperatively exposed lesions [73, 104]. Clinically established imaging modalities provide complementary routes for deeper or disseminated disease. MRI-guided platforms support noninvasive assessment of tumor distribution, vascular permeability and response, while PET- and SPECT-based approaches provide quantitative whole-body biodistribution data for tumor accumulation, off-target exposure and patient-level variability [72, 74, 86–88]. Radionuclide-linked nanotherapeutics connect imaging, dosimetry and localized radiation delivery, with translational issues related to radiolabel stability, normal-tissue dose, long-term retention and sequencing with systemic therapies [72, 74, 85, 89]. Across these modalities, clinical value depends on whether imaging informs patient selection, delivery confirmation, dose planning or response monitoring. From mechanisms to applications: translational considerations for TME-oriented nanoplatforms The strategies discussed in previous sections are grounded in mechanistic insights and preclinical models. For TME-oriented nanoplatforms to move beyond conceptual appeal, they need to be assessed in relation to route of administration, clinical evidence, directness of TME effect, biomarker use, CMC feasibility, safety and value [21, 62, 105]. Route of administration determines exposure, spatial control and regimen sequencing for TME-modulating nanotherapeutics. Systemic administration fits disseminated or inaccessible disease, but depends on circulation time, vascular access, organ clearance and patient-level variation in tumor accumulation. Intratumoral or local administration increases regional exposure and spatial control, especially for immune agonists, photothermal or photodynamic constructs and locally activated theranostic systems; its use is constrained by lesion accessibility, intratumoral distribution, repeat dosing feasibility and the risk of treating only selected lesions in multifocal disease. Route choice also shapes sequencing, as vascular normalization must align with the payload delivery window, stromal modulation may need to precede or accompany drug delivery, and immune priming follows a different timing logic from direct intratumoral reprogramming. These route-dependent considerations are summarized together with evidence level, direct or inferred TME effects, biomarker use and translational bottlenecks in Table 2. Table 2Clinical readiness and translational bottlenecks of representative TME-oriented nanotherapeutic platformsRepresentative strategyRouteEvidence levelTME effectBiomarker/readoutMain translational bottleneckPK-optimized long-circulating nanoformulationsMainly intravenousClinical for approved exposure-modifying nanomedicines; TME-specific effects mostly indirectMostly inferredPK profile, tumor accumulation, toxicity profile, response outcomesVariable human EPR effect and limited prediction of patient-level tumor accumulationLigand-targeted nanoparticlesMainly intravenous or localMostly preclinical; selected early clinical studiesOften inferred from uptake and efficacyReceptor expression, cellular uptake, biodistributionImproved internalization may not increase total tumor accumulationVascular-normalizing platforms, including CRLX101-related strategiesMainly intravenousPreclinical plus early clinical/pharmacodynamic evidence for selected platformsDirect in some studies; inferred in othersHIF-1α-related markers, hypoxia markers, vessel morphology, perfusion or drug distributionNormalization window, scheduling with PK/release profile, mixed clinical outcome signalsStromal or matrix-modulating platformsMainly intravenous; some local modelsMostly preclinicalDirect in matrix-focused modelsECM density, collagen/hyaluronan content, penetration depth, interstitial pressureStromal-depletion paradox, CAF heterogeneity and risk of excessive stromal suppressionEndogenous TME-responsive release systemsMainly intravenous; some local modelsMostly preclinicalDirect when trigger activation is measured; inferred when based on efficacy aloneTrigger activity, release kinetics, activated payload distribution, non-responsive controlsLimited trigger specificity, spatial heterogeneity and complex release characterizationImmune-oriented platformsSubcutaneous, intradermal, intravenous or intratumoral depending on designExtensive preclinical; early-phase clinical testing for selected vaccine or immune agonist platformsDirect for measured immune changes; secondary for downstream TME effectsLymph-node accumulation, dendritic-cell uptake, antigen-specific T cells, TAM phenotype, CD8/Treg ratio, cytokinesDistinguishing systemic priming from local reprogramming; immune toxicity and response heterogeneityImaging-guided and theranostic platformsMainly intravenous or local, with modality-specific activation or imagingMostly preclinical; early clinical relevance varies by modalityDirect when imaging quantifies delivery, activation or dosimetryOptical/NIR signal, MRI contrast, PET/SPECT signal, biodistribution, dosimetry, response monitoringTissue penetration for optical systems; radiolabel stability, normal-tissue dose, workflow and regulatory complexity for nuclear approaches Clinical readiness and translational bottlenecks of representative TME-oriented nanotherapeutic platforms Beyond platform-specific readiness, broader translational constraints determine whether TME-guided designs can become part of routine cancer care. Figure 2 synthesizes these considerations into a constraint-aware development framework that integrates data-driven design prioritisation, TME-informed patient stratification, rational platform simplification and regimen-level coordination. Translational development pathway for TME-oriented multifunctional nanotherapies. The framework integrates data-driven design prioritisation, TME-informed patient stratification, rational platform simplification and regimen-level coordination Approved products and emerging TME-oriented candidates Approved nanomedicines in oncology are still dominated by formulations centered on exposure modification, with limited explicit TME remodeling. Liposomal doxorubicin, albumin-bound paclitaxel and several liposomal formulations of irinotecan and cisplatin are representative examples [106–108]. Their primary rationale is to smooth plasma concentration–time profiles, exploit passive accumulation and reduce specific toxicities such as cardiotoxicity, hypersensitivity to solvents or certain hematological events [106, 108]. Meta-analyses and randomized trials generally show incremental gains: modest improvements in response rates or progression-free survival, and in some settings better tolerability, with limited evidence of major overall-survival improvement [108]. From a TME perspective, these products embody a drug-centered nanonisation paradigm. They take advantage of altered vascular permeability and impaired lymphatic drainage but do not systematically use TME biology to guide design. They also provide important real-world constraints: even with relatively simple compositions and a limited number of quality attributes, the magnitude of clinical benefit tends to be moderate. This experience sets a realistic baseline for what can be expected from more complex, TME-focused constructs [21, 105, 109]. A smaller group of candidates more closely reflects the TME-oriented logic in Sect. 3. CRLX101, a cyclodextrin-based camptothecin nanoparticle, is one of the most studied examples [93]. Preclinical work and early clinical trials indicate preferential intratumoral accumulation, sustained inhibition of topoisomerase I and hypoxia-inducible factor 1 alpha (HIF-1α), and downregulation of HIF-1α-related markers such as carbonic anhydrase IX in human tumor biopsies [90–92]. In rectal cancer chemoradiotherapy and metastatic renal cell carcinoma combinations, CRLX101 has produced signals consistent with vascular normalization and radiosensitization, although randomized trials have so far shown mixed results for hard outcomes such as progression-free survival [91, 92]. On the immune side, several nanovaccine and stimulator of interferon genes (STING) agonist formulations are now moving from preclinical proof of concept into early clinical testing [76, 77]. These systems often deliver antigens and adjuvants or cyclic dinucleotide STING agonists within lipid or polymeric carriers, aiming to enhance dendritic cell uptake, support type I interferon responses and improve the depth of response when combined with checkpoint blockade [76, 77, 81]. Early trials have confirmed pharmacodynamic markers such as interferon induction, T cell activation and local remodeling of cytokine profiles, but durable survival benefits remain to be established [76, 81, 83]. Scale-up manufacturing and CMC challenges Manufacturing considerations are a critical filter between elegant designs and usable medicines. For marketed nanomedicines, production processes have been optimized to generate fairly simple particle architectures [62, 106]. Critical quality attributes are captured within a manageable set of variables, typically including particle size distribution, drug loading, residual solvents, surface charge and relatively straightforward release profiles. These parameters can be monitored and controlled through established analytical methods, which facilitates regulatory evaluation [62, 106]. By contrast, the multifunctional platforms described in Sect. 3 often integrate vascular or stromal modulators, immune regulators, imaging agents and stimuli-responsive components within a single construct. Scaling such systems up requires control over particle size, drug loading, active-agent ratios [21, 109], linker integrity, ligand density and stimuli-responsive behavior. Each additional functional layer adds another axis to the CMC problem [21, 109]. Batch-to-batch consistency becomes harder to document, and the analytical burden to define what constitutes an acceptable product increases substantially. Biomimetic strategies such as cell membrane cloaking, hybrid liposome–exosome shells or multiligand co-decoration can sharpen TME targeting or immune evasion in preclinical models [63, 110]. They also introduce new forms of variability. Donor-derived materials may differ in protein composition and glycosylation [63, 110]. Complex surface architectures can change subtly in response to process conditions or storage. In these settings, the relationship among structure, process and performance may be difficult to express in the relatively compact frameworks that regulators expect for CMC documentation. For TME-oriented platforms, this means that the degree of functional integration is constrained by both biological requirements and manufacturability. A practical design path often involves defining, at an early stage, which modules are essential and which can be omitted without losing the core mechanism [21, 53]. Parallel evaluation of process scalability, stability under realistic storage conditions and the measurability of critical quality attributes can prevent situations in which conceptually attractive constructs prove impossible to manufacture at commercial scale. In this sense, moderate functional integration aligned with a robust, well-characterized process may have more translational potential than designs that maximize complexity at the expense of CMC feasibility. Once such manufacturable designs are in place, the next question is how their altered distribution and TME interactions translate into safety, both for patients and for those who produce and handle these materials. Safety, nanotoxicology and ESHS Safety considerations for TME-oriented nanoplatforms operate at several levels. Clinically, experience with existing nanomedicines illustrates that particle-based delivery reshapes toxicity profiles and requires systematic toxicity characterization. Liposomal encapsulation of anthracyclines can reduce acute cardiotoxicity, yet increase the incidence of hand–foot syndrome [111, 112]. Albumin-bound paclitaxel avoids certain solvent-related hypersensitivity reactions, but is still associated with peripheral neuropathy and myelosuppression [108]. These shifts are acceptable when benefits in efficacy or tolerability are clear, but they underscore the need for systematic characterization because nanonisation should not be assumed to be inherently safer. Platforms that remodel vasculature and stroma raise specific questions about microenvironmental effects in non-target tissues. Agents that normalize tumor vessels or loosen extracellular matrix may have off-target actions in healthy organs, especially in tissues with active remodeling such as bone marrow, gut or healing wounds. Immune reprogramming systems must be evaluated against a background of heterogeneous host immunity. The same stimulus that restores cytotoxic T cell activity in an exhausted TME could, in a different context, promote excessive inflammation or autoimmunity. For theranostic platforms that incorporate metallic cores, high-Z elements for radiosensitization or enzyme-mimetic nanozymes, questions extend to long-term organ accumulation, interference with physiological enzymes and interactions with other medical procedures such as imaging or radiotherapy [85, 113]. Beyond patient-level safety, production and disposal introduce concerns about occupational and environmental exposure. Workers may be exposed to nanoparticulate materials through inhalation, skin contact or accidental ingestion [114]. Waste streams can carry nanomaterials into water or soil if not properly managed. Current regulatory frameworks often handle nanomaterials under general chemical safety regulations with case-by-case additional requirements, and comprehensive environment-safety-health (ESHS) standards for complex multifunctional platforms are not yet fully developed [89, 114]. This uncertainty can translate into more conservative risk assessments and slower approval timelines. For developers, integrating safety and ESHS thinking early in the design process may therefore be as important as achieving a desired biological effect. Choices of core materials, degradation pathways and excipients; decisions about whether to include metals or persistent components; and plans for monitoring long-term outcomes can all influence both regulatory acceptance and societal confidence in large-scale deployment. Even if these conditions are met, however, the clinical and economic value of TME-oriented platforms will still depend on how they perform within a biologically heterogeneous landscape. Biological heterogeneity and value assessment Even if manufacturing and safety hurdles are overcome, the biological heterogeneity of the tumor microenvironment remains a central challenge for the clinical and economic value of TME-oriented nanoplatforms [67, 115]. The degree of vascular permeability, the density and composition of the extracellular matrix and the balance of immune cell subsets differ across tumor types, among patients with the same diagnosis and between individual lesions in one patient [115]. Strategies such as vascular normalization, matrix loosening or immune reprogramming, which perform well in certain preclinical models, may therefore have variable effective doses and safety windows in real-world populations [66, 67]. Multimodular platforms tend to be costly to develop and produce. Without some form of biological stratification, their average benefit across unselected patient populations may not justify these costs. From a health economics and outcomes research perspective, the key question is in whom a platform works well enough to yield acceptable cost-effectiveness ratios and manageable budget impact [116]. A more feasible translational path is to embed TME-related biomarkers and functional imaging into early development. Dynamic contrast-enhanced MRI, positron emission tomography tracers of hypoxia or fibroblast activity, and immune profiling of tumor biopsies can help identify patients with vascular, stromal or immune features that match a given TME modulation strategy [86–88]. When combined with prospective economic evaluations, these tools can support focused indications in which biological plausibility, clinical benefit and cost-effectiveness are aligned [116]. Rather than aiming for broad use across all solid tumors, TME-oriented nanoplatforms may find their place in more narrowly defined subgroups where they can deliver sufficient incremental benefit to justify their complexity. These translational constraints are consolidated in Table 3, which summarizes the key challenges, development implications and potential approaches for TME-oriented multifunctional nanoplatforms. Table 3Translational challenges for TME-oriented multifunctional nanoplatforms and potential approachesTranslational domainKey challenges for TME-oriented multifunctional nanoplatformsImplications for development and deploymentPotential approaches and toolsClinical evidence and product landscape(Sect. 4.1) [21, 109]TME effects mainly shown as PK/biomarker signals; few mature survival data; most approved products are exposure-modifyingDifficult to demonstrate added value over existing nanomedicines and systemic therapies; weak basis for broad adoptionIncorporate TME imaging/biopsy readouts in trials; select indications and combinations with strong TME rationale; include comparators using approved nanomedicinesCMC and scale-up manufacturing(Sect. 4.2) [62, 63]Multi-component, stimuli-responsive designs; complex architectures; hard to control ratios, ligand density, response behaviour at scaleHigh CMC risk; slower development and review; potential instability and cost barriers in routine useDefine essential vs optional modules early; favour robust, scalable processes; establish CQAs linking structure, process and performanceSafety, nanotoxicology and ESHS(Sect. 4.3) [113, 117, 118]Toxicity profiles reshaped, not uniformly reduced; possible off-tumour vascular/ECM and immune effects; long-term accumulation and occupational/environmental exposure uncertainNeed for extended safety monitoring; regulatory caution; concerns about manufacturing and disposalPrefer degradable, low-accumulation materials; design studies to capture organ and immune toxicities; plan long-term follow-up; integrate occupational/environmental risk assessmentBiological heterogeneity and value assessment (Sect. 4.4) [11, 116]Strong inter- and intra-tumour TME variation; high R&D and production costs for multimodular platformsAverage benefit in unselected populations may not justify complexity and cost; reimbursement and access remain uncertainUse TME biomarkers and functional imaging for stratification; focus complex platforms on defined subgroups; pair trials with prospective cost-effectiveness and budget-impact analyses Translational challenges for TME-oriented multifunctional nanoplatforms and potential approaches Clinical evidence and product landscape (Sect. 4.1) [21, 109] CMC and scale-up manufacturing (Sect. 4.2) [62, 63] Safety, nanotoxicology and ESHS (Sect. 4.3) [113, 117, 118] Future directions Work on multifunctional nanoplatforms that engage the TME has built a substantial experimental foundation, but remains constrained by data fragmentation, manufacturing complexity and biological heterogeneity. Future developments are therefore more likely to reorganize and simplify within existing frameworks than to continuously add new functional layers to individual particles. One direction concerns the use of artificial intelligence and data-driven design to explore a broader and more systematic design space [21, 119]. At present, many studies report particle size, surface chemistry and module configurations under heterogeneous conditions, with limited, comparable readouts of TME modulation. If sufficiently large datasets were accumulated under harmonized standards that link nano-bio interface parameters and module combinations to perfusion changes, penetration depth or immune cell composition, these datasets could then serve as a basis for machine learning analyses. Such models might help identify promising design motifs and module assemblies for defined TME phenotypes [109]. Biological interpretation and validation would remain grounded in mechanistic studies, but the experimental search space could be narrowed. A second direction lies at the clinical interface. Patient selection for nanotherapy still relies largely on histology and line of treatment. A gradual shift towards TME-informed stratification may help align multifunctional designs with the populations in which they are most likely to be effective. Functional imaging, liquid biopsy and spatial omics can jointly characterize vascular and stromal status, immune infiltration patterns and metabolic features, and on this basis group tumors into a limited number of TME subtypes. Each subtype could then be matched to a relatively simple but focused nanoplatform that targets its dominant barriers, which may improve predictability of treatment effects and support more favorable cost-effectiveness profiles [11, 116]. Multifunctionality itself may also need to be reconsidered. Existing experience indicates that platforms with many components and highly refined architectures face increasing pressure in process scale-up, quality characterization and safety evaluation. Future designs are likely to place more emphasis on rational simplification: after identifying one or two key TME barriers for a given indication, only functions that are closely aligned with those barriers would be retained, and embedded into carriers with mature manufacturing routes and well-characterized parameters [21]. Some emerging technologies may be better positioned as external partners coordinated with nanomedicine at the regimen level. TME-responsive microrobots, CRISPR-based gene regulation systems and oncolytic viruses with microenvironment-adaptive properties can be scheduled or spatially coordinated with nanomedicine without being physically integrated into the same construct. Regimen-level coordination may extend TME-editing strategies while preserving manufacturability and regulatory tractability. Conclusion Persistent barriers in solid tumor therapy, including uneven drug penetration, hypoxia- and acidosis-associated resistance and local immunosuppression, reflect structural and functional imbalances in the TME. Multifunctional nanoplatforms are most valuable when these barriers are translated into clear design objectives, including improved tumor access and retention, vascular and stromal normalization, TME-responsive release or activation, immune priming or intratumoral reprogramming, and imaging-guided treatment planning. The field is therefore moving toward a more selective form of multifunctionality. Pharmacokinetic optimization, vascular and stromal modulation, TME-responsive activation, immune intervention and imaging guidance are most useful when they are matched to dominant TME phenotypes and supported by measurable readouts. This perspective also exposes the limits of many current designs. EPR-based delivery remains heterogeneous in human tumors, active targeting does not guarantee whole-tumor accumulation, stromal intervention requires careful distinction between normalization and depletion, and immune-oriented platforms must separate systemic priming from local reprogramming. These issues help explain why many elegant preclinical constructs still face uncertain clinical translation. Future progress will depend on phenotype-matched designs with clear biological purposes, measurable evidence and feasible translational paths, with rational simplification likely to be more clinically useful than further functional stacking. Author contributions Mengqi Yang conceived the overall concept of the review, designed the analytical framework, conducted the literature search and synthesis, and drafted the manuscript. Lin Zhang provided overall academic supervision, contributed to the conceptual development of the work, and critically reviewed and revised the manuscript for important intellectual content. Yedong Huang, Weiye Qian, Junye Zhu, and Liu Fei contributed to literature collection, domain-specific discussions, and verification of technical accuracy. Zhixin Jiao, Jian Wang, Yifan Wang, and Wenbo Zhu provided subject-matter input on nanotechnology, tumor microenvironment biology, and translational considerations. Shun Chen, Peipei Gong, Ziheng Wang, Zhichao Lu, Rujun Liu, Zhining Liu, Qiaojun Hong, and Qingyu Luo assisted with reference checking, figure-related discussions, and manuscript revision. All authors reviewed and approved the final version of the manuscript. Funding This review received no specific funding from public, commercial, or not-for-profit entities. The design, analysis, interpretation, and manuscript preparation were conducted independently by the authors without involvement from any sponsors or funders. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. This article is a review and did not involve human participants, human data, human tissue, or animal experiments. Consent for publication Not applicable. Provenance and peer review Not commissioned; externally peer reviewed. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.